News

The discovery of dendritic cells in 1973, resulting in a 2011 Nobel Prize in Physiology or Medicine, bridged the two principal aspects of immunity (innate and adaptive) first

The Company will use the information generated to advance one or more candidates into formal development studies in the coming months. Prosonix’ MCP Technology allows the combination of

These grants support a global intellectual property estate broadly covering the Company’s biochemistry and delivery technologies with over 100 issued or allowed patents and over 90 pending U.S.

The supplement features a discussion on available clinical evidence from trials conducted in patients with diabetic foot ulcers (DFUs). The authors, Dr. Lawrence Lavery, Professor of Surgery, University

Paul DiTullio, Vice President, Product Development remarked, "The major advantages of the Company’s nanoRNA technology over other antisense, gene-silencing and RNAi technologies is a proprietary chemistry that overcomes

The Phase IIb trial was assessing the safety and tolerability of Oxycyte in patients with severe non-penetrating traumatic brain injury (STOP-TBI). The decision to halt the trial comes

The company intends to submit an investigational new drug (IND) application for VT-1129 to the FDA in the first half of 2015. In preclinical trials, VT-1129 has been

The Phase III PIONEER I trial showed that Humira is effective in reducing common clinical signs and symptoms in moderate-to-severe HS, specifically the number of abscesses and inflammatory

The trial will assess the effect of dosing with GEN-004 on the frequency, magnitude and duration of colonization by pneumococcus in the nasopharynx of healthy adults. About 90